# Vaxart, Inc.: Form 10-Q for the period ended Sep 26, 2009

- Company: [Vaxart, Inc.](/companies/vxrt.md) (CIK 72444)
- Form: 10-Q
- Filed: 2009-11-05
- Accepted by EDGAR: Nov 5, 2009, 22:26 ET
- Period: 2009-09-26
- Accession: 0001193125-09-225791
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/72444/000119312509225791/d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/72444/000119312509225791/

## Management's discussion and analysis

As filed, 25,641 characters.

### FORWARD LOOKING STATEMENTS

*Statements in this quarterly report that are not strictly historical are forward-looking statements and include statements about products in development, results and analyses of clinical trials and studies, research and development expenses, cash expenditures, licensure applications and approvals, and alliances and partnerships, among other matters. You can identify these forward-looking statements because they involve our expectations, intentions, beliefs, plans, projections, anticipations, or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our ability to: successfully partner with third parties to fund, develop, manufacture and/or commercialize our products in development; initiate and conduct clinical trials and studies; raise sufficient new capital resources to fully develop and commercialize our products in development; attract, retain and motivate key employees; collect further milestone and royalty payments under the PhosLo Agreement; collect milestone payments under the Staph program asset purchase agreement with GSK; obtain regulatory approval for our products in the U.S. or other markets; successfully contract with third party manufacturers for the manufacture and supply of NicVAX; and comply with reporting and payment obligations under government rebate and pricing programs. Some of these factors are more fully discussed, as are other factors, in our Annual Report on Form 10-K for the fiscal year ended December 27, 2008 filed with the Securities and Exchange Commission and under “Risk Factors” in this Quarterly Report. We do not undertake to update any of these forward-looking statements or to announce the results of any revisions to these forward-looking statements except as required by law.*

The following is a discussion and analysis of the major factors contributing to our financial condition and results of operations for the three and nine months ended September 26, 2009 and September 27, 2008. The discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto.

### RECENT EVENTS

In November 2009, we completed the sale to GSK of all the assets, including intellectual property and related rights, to our Staph program (including *S.aureus* and *S.epidermidis*) and received $21.5 million in cash pursuant to the terms of our asset purchase agreement with GSK dated August 5, 2009, as amended. Under the terms of the asset purchase agreement, we have the right to receive up to an additional $26 million contingent upon certain milestone accomplishments. At the closing, we also entered into a transition services agreement with GSK to provide services to GSK related to the planned Phase I clinical trial and technology transfer related to the assets sold to GSK. We will be reimbursed for our cost of services provided under this agreement. We anticipate beginning to recognize revenue related to this arrangement in the fourth quarter of 2009 as we start fulfilling our contractual obligations.

In September 2009 we announced that NIDA granted us $10 million to partially fund our first NicVAX pivotal Phase III trial, which we initiated during the fourth quarter of 2009. We expect to recognize the grant funding as a reduction in our research and development expenses in the periods incurred.

### OVERVIEW

We are a biopharmaceutical company focused on the development of products that address unmet medical needs in the areas of nicotine addiction and infectious disease. We leverage our experience and knowledge in powering the human immune system to target serious medical conditions in these areas. Our products in development are NicVAX \[*Nicotine Conjugate Vaccine*\], an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse, and PentaStaph \[*Pentavalent S.aureus Vaccine*\], a new pentavalent vaccine designed to prevent *S.aureus* infections including those infections caused by the most dangerous antibiotic-resistant strains of *S.aureus.*

#### Products in Development

NicVAX is an investigational vaccine based on patented technology. Nicotine, a non-immunogenic small molecule, can cross the blood-brain barrier and reach specific receptors in the brain, thereby leading to the highly addictive pleasure sensation experienced by smokers and users of nicotine products. NicVAX is designed to stimulate the immune system to produce highly specific antibodies that bind to nicotine. A nicotine molecule attached to an antibody is too large to cross the blood-brain barrier, and thus is unable to reach the receptors in the brain and trigger pleasure sensations. In November 2007, we announced the successful completion of a Phase IIb “proof-of-concept” clinical trial for NicVAX that showed statistically significant rates of smoking cessation and continuous long-term smoking abstinence at 6 and 12 months for subjects injected with NicVAX as compared with subjects injected with placebo. In October 2008, we announced the results of a Phase II schedule optimization immunogenicity study assessing the antibody response and safety of a six-dose immunization schedule. This study showed that significantly higher antibody levels can be generated earlier in a higher percentage of subjects than in previous studies and that the revised dose regimen continued to be well-tolerated. These key results have guided our design for the NicVAX Phase III trials. In December 2008, we announced that we had reached agreement with the FDA on a SPA for the pivotal Phase III clinical trials for NicVAX, which we are in a position to initiate in 2009. The SPA forms the foundation to support approval of a NDA. In June 2009, we announced that we received scientific advice on NicVAX from the EMEA regarding the requirements for marketing authorization submission relating to the appropriate design of the Phase III clinical studies and safety data. This advice confirms and supports our current Phase III design that was agreed to in the SPA. In September 2009 we announced that NIDA, part of the NIH, granted us $10 million to partially fund our first NicVAX pivotal Phase III trial, which we initiated during the fourth quarter 2009. We continue seeking a partner who will assist in further development and future commercialization of NicVAX.

PentaStaph is an investigational vaccine based on patented technology, including some technology that we have licensed on an exclusive basis from NIH. We are developing PentaStaph for use in patients who are at high risk of *S.aureus* infection and who are able to respond to a vaccine by producing their own antibodies. PentaStaph requires additional development, including human clinical studies, as well as regulatory approvals before it can be marketed. We announced two significant events in 2008 that help advance the development of PentaStaph. In September 2008, we entered into a collaboration agreement with the NIAID to conduct pre-clinical toxicology evaluations of two new antigens designed to protect against two of the most virulent and debilitating toxins produced by the bacteria. This testing, which was completed in 2009, was funded by the NIAID and is a pre-requisite to the initiation of Phase I clinical trials for these new antigens in 2009. Additionally, in December 2008, we entered into a research and development agreement with the U.S. Department of Defense to conduct a series of collaborative clinical trials for PentaStaph. The U.S. Department of Defense will be responsible for certain aspects of the trial including the clinical site costs. In November 2009, we completed the sale to GSK of all the assets, including intellectual property and related rights, to our Staph program (including *S.aureus* and *S.epidermidis*) and received $21.5 million in cash pursuant to the terms of our asset purchase agreement with GSK dated August 5, 2009, as amended. Under the terms of the asset purchase agreement, we have the right to receive up to an additional $26 million contingent upon certain milestone accomplishments. At the closing, we also entered into a transition services agreement with GSK to provide services to GSK related to the planned Phase I clinical trial and technology transfer related to the assets sold to GSK. We will be reimbursed for our cost of services provided under this agreement.

#### Strategic Initiatives

In 2006, we began to explore strategic initiatives to enhance shareholder value. In November 2006, we sold our PhosLo (calcium acetate) product and the product’s related assets to a U.S. subsidiary of Fresenius Medical Care, or Fresenius. Under the sale agreement, we received $65.0 million in cash at closing and received an additional $13.0 million of milestone payments as of September 26, 2009. We can also receive royalties and additional milestone payments up to $72.5 million. The royalties relate to sales of a new product formulation over a base amount for 10 years after the closing date. In June 2007, we sold certain assets related to our product Aloprim (allopurinol sodium for Injection) for $3.7 million. On December 4, 2007, we sold our Biologics SBU and certain corporate shared services assets to Biotest Pharmaceuticals Corporation, or Biotest, for $185.0 million. In November 2009, we completed the sale to GSK of all assets, including intellectual property and related rights, to our Staph program (including *S.aureus* and *S.epidermidis*) and received $21.5 million in cash at closing.

As a result of these strategic actions, we sold all our marketed products as well as our Staph vaccine development program and are focused on developing and partnering our NicVax product. In September 2009, we were granted $10 million by NIDA to partially fund our Phase III trial for NicVAX. We are continuing to explore the full range of strategic alternatives available to us to further enhance shareholder value. These alternatives may include, but are not limited to, licensing or further development arrangements for NicVAX, joint ventures, strategic alliances, a recapitalization, and the sale or merger of all or part of the company.

### RESULTS OF OPERATIONS

Effective January 1, 2009, we adopted new accounting guidance relating to our Convertible Senior Notes. The new accounting guidance clarifies that (1) convertible debt instruments that may be settled in cash upon conversion, including partial cash settlement, are not considered conventional debt instruments and (2) issuers of such instruments should separately account for the liability and equity components of those instruments by allocating the proceeds from issuance of the instrument between the liability component and the embedded conversion option (i.e., the equity component). The new accounting guidance is effective for fiscal years beginning after December 15, 2008 and is required to be applied retrospectively to convertible debt instruments that are within the scope of this guidance and were outstanding during any period presented in the financial statements. We adopted the new guidance in the first quarter 2009. The cumulative effect of the adoption as of December 30, 2007 (the first day of our 2008 fiscal year) was a $25.4 million increase in capital in excess of par, a $17.4 million increase in accumulated deficit, a $7.3 million net increase in the convertible note balance and a $0.7 million net increase in other assets with no effect on our net consolidated cash and cash equivalents or our cash interest payments for the period. The effect of the adoption on the three- and nine-month periods ended September 26, 2009 was a $0.1 million and $0.4 million increase in interest expense, respectively.

### FOR THE THREE MONTHS ENDED SEPTEMBER 26, 2009 AND SEPTEMBER 27, 2008

*General and administrative expenses*. General and administrative expenses were $2.4 million for the third quarter of 2009 compared to $2.1 million for the third quarter of 2008. The increase of $0.3 million reflects higher levels of legal costs associated with the strategic alternatives process as well as to support our response to the Biotest claim, offset in part by reduced stock-based compensation expenses. We expect our full-year 2009 general and administrative expenses to be below 2008 levels.

*Research and development expenses*. Research and development expenses were $4.7 million for the third quarter of 2009 compared to $3.4 million for the third quarter of 2008. Research and development increased approximately $1.3 million in 2009 as a result of increased efforts to prepare for our planned Phase III NicVAX trial including manufacturing-related activities. Our research and development costs are expected to increase in the fourth quarter 2009 as a result of increased spending to support the PentaStaph Phase I trial and the NicVAX Phase III trial. The cost of the PentaStaph Phase I clinical trial will be reimbursed by GSK and a portion of the costs for the NicVAX trial will be offset by the receipt of grant funding by NIDA.

*Interest income*. Interest income was $0.1 million and $0.8 million for the third quarters of 2009 and 2008, respectively. Interest earned on our cash and investments was lower in the third quarter 2009 as compared to the third quarter 2008 due to lower average cash balances and lower interest rates in general.

*Interest expense.* Interest expense was $0.1 million and $0.8 million for the third quarters of 2009 and 2008, respectively. The decrease in interest expense reflects the impact of a lower debt level in 2009 as compared to 2008.

*Other income (expenses), net*. We adopted new accounting guidelines for our Convertible Senior Notes in the first quarter of 2009, and retrospectively applied the new guidelines to 2008 and prior periods. The new accounting guidelines require that we apportion any gains and losses resulting from the repurchase of our Convertible Senior Notes between equity (for the conversion option) and current period income (loss) (for the liability). In the third quarter of 2008 we repurchased $7.0 million face value of our Convertible Senior Notes at a total discount of $0.8 million. Of this amount, $.02 million was reflected as an increase in other expenses. In the third quarter of 2009 we received $0.1 million of miscellaneous income and did not repurchase any of our Convertible Senior Notes.

*Income from Discontinued Operations (net of taxes).* We had no income from discontinued operations in the third quarter of 2009. By contrast, in the third quarter of 2008, we recognized $2.2 million of income from discontinued operations relating to the arbitration proceeding against Inhibitex, a net reduction in liabilities from discontinued operations of approximately $0.4 million, and provided an intra-period tax provision of approximately $1.0 million.

*Income taxes*. During 2009, we recorded a full valuation allowance against all net deferred tax assets. As a result of this valuation allowance, the effective tax rate for continuing operations for 2009 is 0%. In 2008, we recorded a tax benefit from continuing operations of approximately $1.0 million as a result of intra-period tax allocation.

### FOR THE NINE MONTHS ENDED SEPTEMBER 26, 2009 AND SEPTEMBER 27, 2008

*General and administrative expenses*. General and administrative expenses were $7.8 million for the first nine months of 2009 compared to $10.1 million for the comparable 2008 period. The decrease of $2.3 million reflects the reduced scale of our operations following the sale of our Biologics SBU our continued efforts to reduce overall infrastructure costs as well as a reduction in stock-based compensation expense, offset in part by higher legal fees associated with the strategic alternatives process and support for the Biotest claim.

*Research and development expenses*. Research and development expenses were $11.9 million for the first nine months of 2009 compared to $9.9 million for the comparable 2008 period. The increase of $2.0 million is primarily due to an increase in activities as we prepare for the planned Phase III NicVAX trial including manufacturing-related activities. Our research and development costs are expected to increase in the fourth quarter 2009 as a result of increased spending to support the PentaStaph Phase I trial and the NicVAX Phase III trial. The cost of the PentaStaph Phase I clinical trial will be reimbursed by GSK and a portion of the costs for the NicVAX trial will be offset by the receipt of grant funding by NIDA.

*Interest income*. Interest income was $0.3 million and $4.1 million for the first nine months of 2009 and 2008, respectively. Interest earned on our cash and investments was lower in 2009 as compared to 2008 due to lower average cash balances and lower prevailing interest rates on our investments.

*Interest expense.* Interest expense was $0.6 million and $3.5 million for the first nine months of 2009 and 2008, respectively. The decrease in interest expense reflects the impact of a lower debt level in 2009 compared to 2008.

*Other income (expenses), net*. We adopted new accounting guidelines for our Convertible Senior Notes in the first quarter of 2009, and retrospectively applied the new guidelines to 2008 and prior periods. The new accounting guidelines require that we apportion any gains and losses resulting from the repurchase of our Convertible Senior Notes between equity (for the conversion option) and current period income (loss) (for the liability). In the first nine months of 2008 we repurchased $38.6 million face value of our Convertible Senior Notes at a total discount of $3.5 million. Of this amount, $0.9 million was reflected as an increase in other expenses. In the first nine months of 2009, we repurchased $10.4 million face value of our Convertible Senior Notes at a total discount of $0.3 million with no impact to other expenses. Other income of $0.1 million for the first nine months of 2009 represents miscellaneous income for the period.

*Income from Discontinued Operations (net of taxes).* In the first nine months of 2008, we recognized income from discontinued operations of $2.5 million related to the 2006 sale of our PhosLo product, $2.2 million for the arbitration proceeding against Inhibitex, a net reduction in liabilities from discontinued operations of approximately $1.7 million, and provided an intra-period tax provision of approximately $2.5 million. We had no income from discontinued operations in 2009.

*Income taxes*. During 2009, we recorded a full valuation allowance against all net deferred tax assets. As a result of this valuation allowance, the effective tax rate for continuing operations for 2009 is 0%. In 2008, we recorded a tax benefit from continuing operations of approximately $2.5 million as a result of intra-period tax allocation.

### LIQUIDITY AND CAPITAL RESOURCES

Our cash, cash equivalents and marketable securities at September 26, 2009 totaled $103.3 million compared to $130.3 million at December 27, 2008. This decline is primarily the result of our net cash used in operations along with the payments of approximately $10.1 million for the repurchase of our Convertible Senior Notes and approximately $3.5 million for the repurchases of shares of our common stock, offset partially by the release of $4.5 million of restricted cash related to the sale of our Biologics SBU to Biotest. At September 26, 2009, we had remaining restricted cash of $5.7 million that was held in escrow subject to indemnification claims by Biotest. This cash was released to us in November 2009 in connection with our settlement with Biotest (see Note 4 of the condensed consolidated financial statements for further discussion).

Cash used in operating activities from continuing operations for the nine months ended September 26, 2009 was $18.1 million, compared to $16.0 million for the nine months ended September 27, 2008. The increase in cash used was primarily associated with increased research and development expenses and lower payable balances offset in part by the reduced general and administrative expenses in 2009. Cash used in investing activities from continuing operations for the nine months ended September 26, 2009 was $51.3 million, consisting largely of the net purchases of our marketable securities.

In 2007, our Board of Directors approved the repurchase of up to $65 million of our common stock in the open market or in privately negotiated transactions. In the first nine months of 2009, we acquired a total of 1,064,997 shares for a total cost of $3.1 million under the program. In addition, as purchases of treasury shares are accounted for on the trade date, the settlement of trades executed in the fourth quarter of 2008 which were settled in the first quarter of 2009 increased the cash used to purchase treasury shares in the first quarter by $0.4 million to $3.5 million as reported in the Condensed Consolidated Statement of Cash Flows. In 2005, we issued $112.4 million of Convertible Senior Notes through a private offering to qualified institutional buyers as defined under Rule 144A of the Securities Act of 1933, as amended, the Securities Act. Net cash proceeds from the offering totaled $108.7 million. In 2007 we repurchased $38.8 million of our Convertible Senior Notes and in 2008 we repurchased an additional $57.3 million of our Convertible Senior Notes. In 2009 we repurchased an additional $10.4 million of our Convertible Senior Notes and we paid $10.1 million for the notes. As of September 26, 2009, we have approximately $6.1 million face value of our Convertible Senior Notes outstanding. Interest on our Convertible Senior Notes is payable on each April 15 and October 15, beginning October 15, 2005. We can redeem our Convertible Senior Notes at 100% of their principal amount, plus accrued and unpaid interest, any time on or after April 18, 2010. Holders of our Convertible Senior Notes may require us to repurchase our Convertible Senior Notes for 100% of their principal amount, plus accrued and unpaid interest, on April 15, 2010, April 15, 2012, April 15, 2015 and April 15, 2020, or following the occurrence of a change in control as defined in the indenture agreement governing the Notes. We may continue to repurchase our Convertible Senior Notes in the open market or in privately negotiated transactions.

We believe cash, cash equivalents and marketable securities on hand at September 26, 2009, together with the $5.7 million of restricted cash that was released to us in November 2009, $21.5 million in purchase price received in connection with the closing of the Staph program sale in November 2009 and the anticipated proceeds from the $10 million NIDA grant awarded to partially fund our NicVAX Phase III trial, will be sufficient to meet our anticipated cash requirements for operations and debt service for at least the next 12 months.

### CRITICAL ACCOUNTING POLICIES

Note 3 to our condensed consolidated financial statements includes a discussion of our significant accounting policies. We believe that the following policies and estimates are critical because they involve significant judgments, assumptions and estimates. We have discussed the development and selection of our critical accounting estimates with the Audit Committee of our Board of Directors and the Audit Committee has reviewed the disclosures presented below relating to those policies and estimates:

*Accounting estimates:* The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period, including such amounts related to discontinued operations. Actual results could differ from those estimates.

*Research and development expenses:* Except for advance payments, research and development costs are expensed as incurred. We use our research and development resources, including employees, equipment and facilities, across multiple drug development programs. Research and development expenses include direct labor costs as well as the costs of contractors and other direct and indirect expenses, (including an allocation of the costs of facilities). We expense amounts payable to third parties under collaborative product development agreements at the earlier of the milestone achievement or as payments become contractually due. In circumstances where we receive grant income (which is a reimbursement to research and development costs incurred), we record the income as an offset to the related expense.

*Equity-based compensation*: We currently account for equity-based compensation at fair value; accordingly we expense the estimated fair value of share-based awards made in exchange for employee services over the requisite employee service period. Share-based compensation cost is determined at the grant date using an option pricing model. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee’s requisite service period.

## Controls and procedures

As filed, 1,953 characters.

Our Chief Executive Officer currently serves as acting Chief Financial Officer

As of the end of the period covered by this Quarterly Report, management performed, with the participation of our Chief Executive Officer and Chief Accounting Officer, an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Securities Exchange Act of 1934, as amended, or the Exchange Act, Rules 13a-15(e) and 15d-15(e)). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Accounting Officer, to allow timely decisions regarding required disclosures. Based on this evaluation, management, including our Chief Executive Officer and Chief Accounting Officer, has concluded that as of September 26, 2009, the Company’s disclosure controls and procedures were effective.

There has been no change in our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during our fiscal quarter ended September 26, 2009 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met, and therefore, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. We cannot assure that our disclosure controls and procedures or our internal control over financial reporting are able to prevent with certainty all errors and all fraud.

## Risk factors

As filed, 1,613 characters.

We have entered into a settlement agreement with Biotest concerning certain the release of outstanding claims under the Biotest asset purchase agreement. While we continue to have certain limited indemnification obligations to Biotest under the asset purchase agreement, the Risk Factor included in Item 1A of our Annual Report on Form 10-K for the year ended December 27, 2009 titled “Under the Biologics strategic business unit asset purchase agreement, we will have continuing obligations to indemnify Biotest, and may be subject to other liabilities” is hereby updated by eliminating the risk factor pertaining to our obligations to indemnify Biotest and other related liabilities, including the updates to that risk factor contained in Part II, Item 1A of our Quarterly Reports on Form 10-Q for the quarters ended March 28, 2009 and June 27, 2009.

We further update the Risk Factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 27, 2009, with the following:

We may not collect milestone payments under the Staph program agreement with GSK.

We may not collect any or all milestone payments under the Staph program agreement with GSK. We received $21.5 million in cash at closing related to the sale of our Staph assets and can also receive up to $26 million in milestone payments based upon the satisfaction of four milestone conditions. There can be no assurance of the completion of the milestone conditions. If we are unable to complete the milestone conditions we will not collect any milestone payment associated with the condition that we do not complete.

Filed Nov 5, 2009.
Source: SEC EDGAR, the filing index for accession 0001193125-09-225791. Last ingested by Listed: Nov 5, 2026, 18:48 ET. No prices; not investment advice.
